199 related articles for article (PubMed ID: 32999432)
1. Imatinib is not a potent anti-SARS-CoV-2 drug.
Zhao H; Mendenhall M; Deininger MW
Leukemia; 2020 Nov; 34(11):3085-3087. PubMed ID: 32999432
[No Abstract] [Full Text] [Related]
2. Drug Repurposing Study Pinpoints Potential COVID-19 Antivirals.
Abbasi J
JAMA; 2020 Sep; 324(10):928. PubMed ID: 32897326
[No Abstract] [Full Text] [Related]
3. On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2.
Sauvat A; Ciccosanti F; Colavita F; Di Rienzo M; Castilletti C; Capobianchi MR; Kepp O; Zitvogel L; Fimia GM; Piacentini M; Kroemer G
Cell Death Dis; 2020 Aug; 11(8):656. PubMed ID: 32814759
[TBL] [Abstract][Full Text] [Related]
4. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.
Riva L; Yuan S; Yin X; Martin-Sancho L; Matsunaga N; Pache L; Burgstaller-Muehlbacher S; De Jesus PD; Teriete P; Hull MV; Chang MW; Chan JF; Cao J; Poon VK; Herbert KM; Cheng K; Nguyen TH; Rubanov A; Pu Y; Nguyen C; Choi A; Rathnasinghe R; Schotsaert M; Miorin L; Dejosez M; Zwaka TP; Sit KY; Martinez-Sobrido L; Liu WC; White KM; Chapman ME; Lendy EK; Glynne RJ; Albrecht R; Ruppin E; Mesecar AD; Johnson JR; Benner C; Sun R; Schultz PG; Su AI; García-Sastre A; Chatterjee AK; Yuen KY; Chanda SK
Nature; 2020 Oct; 586(7827):113-119. PubMed ID: 32707573
[TBL] [Abstract][Full Text] [Related]
5. Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In Vitro When Administered After Virus Infection.
Clementi N; Ferrarese R; Criscuolo E; Diotti RA; Castelli M; Scagnolari C; Burioni R; Antonelli G; Clementi M; Mancini N
J Infect Dis; 2020 Aug; 222(5):722-725. PubMed ID: 32559285
[TBL] [Abstract][Full Text] [Related]
6. Are there any Therapeutic Options Currently Available for Wuhan Coronavirus?
Carradori S
Antiinflamm Antiallergy Agents Med Chem; 2020; 19(2):85-87. PubMed ID: 32213152
[No Abstract] [Full Text] [Related]
7. Rapid repurposing of drugs for COVID-19.
Guy RK; DiPaola RS; Romanelli F; Dutch RE
Science; 2020 May; 368(6493):829-830. PubMed ID: 32385101
[No Abstract] [Full Text] [Related]
8. Cationic drugs and COVID-19.
Brenna OV; Torretta S; Pignataro L; Di Berardino F
Int J Immunopathol Pharmacol; 2020; 34():2058738420966078. PubMed ID: 33045858
[TBL] [Abstract][Full Text] [Related]
9. Imatinib for COVID-19: A case report.
Morales-Ortega A; Bernal-Bello D; Llarena-Barroso C; Frutos-Pérez B; Duarte-Millán MÁ; García de Viedma-García V; Farfán-Sedano AI; Canalejo-Castrillero E; Ruiz-Giardín JM; Ruiz-Ruiz J; San Martín-López JV
Clin Immunol; 2020 Sep; 218():108518. PubMed ID: 32599278
[No Abstract] [Full Text] [Related]
10. Uncertainty about the Efficacy of Remdesivir on COVID-19.
Yoo JH
J Korean Med Sci; 2020 Jun; 35(23):e221. PubMed ID: 32537956
[No Abstract] [Full Text] [Related]
11. SARS-CoV-2 RNA polymerase as target for antiviral therapy.
Buonaguro L; Tagliamonte M; Tornesello ML; Buonaguro FM
J Transl Med; 2020 May; 18(1):185. PubMed ID: 32370758
[TBL] [Abstract][Full Text] [Related]
12. Drug Discovery Strategies for SARS-CoV-2.
Shyr ZA; Gorshkov K; Chen CZ; Zheng W
J Pharmacol Exp Ther; 2020 Oct; 375(1):127-138. PubMed ID: 32723801
[TBL] [Abstract][Full Text] [Related]
13. Repurposing old drugs as antiviral agents for coronaviruses.
Yang CW; Peng TT; Hsu HY; Lee YZ; Wu SH; Lin WH; Ke YY; Hsu TA; Yeh TK; Huang WZ; Lin JH; Sytwu HK; Chen CT; Lee SJ
Biomed J; 2020 Aug; 43(4):368-374. PubMed ID: 32563698
[TBL] [Abstract][Full Text] [Related]
14. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Martinez MA
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
[TBL] [Abstract][Full Text] [Related]
15. N-acetylcysteine as a potential treatment for COVID-19.
Jorge-Aarón RM; Rosa-Ester MP
Future Microbiol; 2020 Jul; 15():959-962. PubMed ID: 32662664
[No Abstract] [Full Text] [Related]
16. Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.
Xiong R; Zhang L; Li S; Sun Y; Ding M; Wang Y; Zhao Y; Wu Y; Shang W; Jiang X; Shan J; Shen Z; Tong Y; Xu L; Chen Y; Liu Y; Zou G; Lavillete D; Zhao Z; Wang R; Zhu L; Xiao G; Lan K; Li H; Xu K
Protein Cell; 2020 Oct; 11(10):723-739. PubMed ID: 32754890
[TBL] [Abstract][Full Text] [Related]
17. Drug researchers pursue new lines of attack against COVID-19.
Harrison C
Nat Biotechnol; 2020 Jun; 38(6):659-662. PubMed ID: 32417850
[No Abstract] [Full Text] [Related]
18. Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19.
Saul S; Einav S
ACS Infect Dis; 2020 Sep; 6(9):2304-2318. PubMed ID: 32687696
[TBL] [Abstract][Full Text] [Related]
19. Anti-SARS-CoV-2 Potential of Artemisinins In Vitro.
Cao R; Hu H; Li Y; Wang X; Xu M; Liu J; Zhang H; Yan Y; Zhao L; Li W; Zhang T; Xiao D; Guo X; Li Y; Yang J; Hu Z; Wang M; Zhong W
ACS Infect Dis; 2020 Sep; 6(9):2524-2531. PubMed ID: 32786284
[TBL] [Abstract][Full Text] [Related]
20. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
